Hidrosmin

Chengdu Yazhong Bio-Pharmaceutical Co., Ltd., established in 2002, manufactures cardiovascular-drug active ingredients, vitamins, plant extracts and pharmaceutical intermediates for markets worldwide. The company obtained GMP certification for dehydropregnenolone acetate in 2005 and, for its diosmin product, achieved registration in 2014, GMP/WC certification in 2015 and a CEP in 2017; it became a subsidiary of Jiangsu Lianhuan in 2019 and began construction of a new production plant in 2021, targeting full production by 2023. Operating under its own brand and known for stable supply at favorable prices, the company is recognized for its brand name, international approvals, experienced R&D staff, and production capacity.